162 related articles for article (PubMed ID: 14959470)
1. [Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
Ol'binskaia LI; Danilogorskaia IuA
Ter Arkh; 2003; 75(12):47-50. PubMed ID: 14959470
[TBL] [Abstract][Full Text] [Related]
2. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Tran YB; Frial T; Miller PS
Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
[TBL] [Abstract][Full Text] [Related]
3. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Hirsch M; O'Donnell JC; Jones P
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
[TBL] [Abstract][Full Text] [Related]
5. Drug use evaluation of statins at Siriraj Hospital, 2008.
Suwansuksree N; Thamlikitkul V; Yamwong P
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S179-86. PubMed ID: 20364573
[TBL] [Abstract][Full Text] [Related]
6. Drug use review matters.
Mueting M
Nebr Nurse; 2007; 40(3):28. PubMed ID: 17915614
[No Abstract] [Full Text] [Related]
7. [Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Marta-Moreno J; Echeandia C; Oliveros-Cid A; Figuerola A; Mola S
Rev Neurol; 1998 Nov; 27(159):827-30. PubMed ID: 9859160
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event.
Brudi P; Reckless JP; Henry DP; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO
Cardiology; 2009; 113(2):89-97. PubMed ID: 19018143
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of simvastatin in patients with hypercholesterolemia (results of a Multicenter Clinical Study)].
Kukharchuk VV; Bubnova MG; Katel'nitskaia LI; Nikitin IuP; Ol'binskaia LI;
Kardiologiia; 2003; 43(5):42-7. PubMed ID: 12891239
[TBL] [Abstract][Full Text] [Related]
10. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
12. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Broncel M; Bała A; Koter-Michalak M; Duchnowicz P; Wojsznis W; Chojnowska-Jezierska J
Wiad Lek; 2007; 60(7-8):321-8. PubMed ID: 18175550
[TBL] [Abstract][Full Text] [Related]
16. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
Sedjo RL; Cox ER
Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
[TBL] [Abstract][Full Text] [Related]
17. Achieving vascular risk factor targets: a survey of a London general practice.
Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
[TBL] [Abstract][Full Text] [Related]
18. Switching statins: cost of simvastatin is overestimated.
Ashcroft JS
BMJ; 2006 Jun; 332(7556):1512. PubMed ID: 16793831
[No Abstract] [Full Text] [Related]
19. Rosuvastatin in the management of hyperlipidemia.
Cheng JW
Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
[TBL] [Abstract][Full Text] [Related]
20. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
